Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder

NCT01982643 ↗

Phase 1/2 Completed 49 enrolled Walter Ling National Institute on Drug Abuse (NIDA) · collab The Emmes Company, LLC · collab

NaSingle-groupOpen-labelTreatment

Summary

The aim of this 2-stage, 3-site study is to investigate the effectiveness and safety of a combination of extended-release depot naltrexone plus extended-release bupropion as a potential pharmacotherapy for methamphetamine (MA) use disorder.

Timeline

Start: 2013-11
Primary completion: 2015-02
Completion: 2015-02

Publications

Walker R, Hillhouse M, Perrochet B, Sparenborg S, Mooney L, Ling W. Medication Adherence Monitoring Using Smartphone Video Dosing in an Open-label Pilot Study of Monthly Naltrexone Plus Once-daily Bupropion for Methamphetamine Use Disorder: Feasibility and Acceptability. J Addict Med. 2019 Sep/Oct;13(5):372-378. doi: 10.1097/ADM.0000000000000509.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bupropion	Small molecule	450 mg	Oral
Subject	Naltrexone	Small molecule	—	—

Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder

Summary

Timeline

Publications

Drugs

Indications